Feds go after Mylan for scamming Medicaid out of millions on EpiPen pricing #epipen #medicaid #mylan Over the nine or so years that Mylan, Inc. has been selling—and hiking the price—of EpiPens, the drug company has been misclassifying the life-saving device and stiffing Medicaid out of full rebate payments, federal regulators told Ars.
Regulators warned Mylan multiple times, and now there are “financial consequences."